Group 1 - Kura Oncology is presenting updates on its farnesyl transferase program at the ESMO 2025 Congress, focusing on clinical data [2] - This presentation is the second part of a series, with the first part discussing preclinical data and rationale presented on September 16 [2] - The company has made available the webcast and slides from the previous presentation on its website [2] Group 2 - The presentation includes forward-looking statements regarding the company's future prospects [3]